Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.

One is a 2,600 m² GMP facility that more than doubles peptide API manufacturing capacity. This “will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products”, the company said.

Almac Sciences has completed the first stage of its GMP API facility expansion at its headquarters site in Craigavon, Northern Ireland. This has seen two 1,000 L glass-lined reactors added with associated filtration and drying equipment allowing the manufacture of 50-100 kg batch API output. It complements the R&D technology centre opened in 2021 for the biocatalysis, flow chemistry and peptides businesses.